Novo Nordisk reported DKK12.13B in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
ANI Pharmaceuticals USD 290.77M 24.77M Sep/2026
Aurora Cannabis CAD 67.55M 29.54M Jun/2026
Bausch Health Companies USD 2.94B 90M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Canopy Growth CAD 81.16M 9.91M Jun/2026
Corcept Therapeutics USD 340.5M 84.35M Sep/2026
Drreddys Laboratories INR 86.71B 85.92B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Merck USD 18.1B 1.5B Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.52B 112M Sep/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Novo Nordisk DKK 12.13B 84.69B Jun/2026
Pacira USD 176.65M 15.75M Sep/2026
Perrigo USD 989M 31M Sep/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 265.71M 15.91M Jun/2026
Sanofi EUR 14.44B 2.49B Sep/2026
Supernus Pharmaceuticals USD 226.8M 7.7M Sep/2026
Zoetis USD 2.4B 100M Sep/2026